Centers for Disease Control and Prevention, 1600 Clifton Road, MS-D26, Atlanta, GA 30333, USA.
Vaccine. 2013 Dec 5;31(50):5975-82. doi: 10.1016/j.vaccine.2013.10.031. Epub 2013 Oct 19.
As part of the Centers for Disease Control and Prevention's monitoring and evaluation activities for influenza vaccines, we examined relationships between influenza vaccination and selected outcomes in the 2009-2010 and 2010-2011 influenza seasons in a claims-based data environment.
We included patients with claims for trivalent influenza vaccine (TIV) and/or 2009 pandemic influenza A H1N1 vaccine (H1N1) during the 2009-2010 and 2010-2011 influenza seasons. Patients were followed for several pre-specified outcomes identified in claims. Seizures and Guillain-Barré Syndrome were selected a priori for medical record confirmation. We estimated incidence rate ratios (IRR) using a self-controlled risk interval (SCRI) or a historical comparison design. Outcomes with elevated IRRs, not selected a priori for medical record review, were further investigated with review of claims histories surrounding the outcome date to determine whether the potential event could be ruled-out or attributed to other causes based on the pattern of medical care.
In the 2009-2010 season, no significant increased risks for outcomes following H1N1 vaccination were observed. Following TIV administration, the IRR for peripheral nervous system disorders and neuropathy was slightly elevated (1.07, 95% CI: 1.01-1.13). The IRR for anaphylaxis following TIV was 28.55 (95% CI: 3.57-228.44). After further investigation of claims histories, the majority of potential anaphylaxis cases had additional claims around the time of the event indicating alternate explanatory factors or diagnoses. In the 2010-2011 season following TIV administration, a non-significant elevated IRR for anaphylaxis was observed with no other significant outcome findings.
After claims history review, we ultimately found no increased outcome risk following administration of 998,881 TIV and 538,257 H1N1 vaccine doses in the 2009-2010 season, and 1,158,932 TIV doses in the 2010-2011 season.
作为疾病预防控制中心监测和评估流感疫苗活动的一部分,我们在基于索赔数据的环境中,研究了 2009-2010 年和 2010-2011 年流感季节中流感疫苗接种与选定结果之间的关系。
我们纳入了在 2009-2010 年和 2010-2011 年流感季节中接受三价流感疫苗(TIV)和/或 2009 年甲型 H1N1 流感疫苗(H1N1)接种的患者。对患者进行了随访,以确定在索赔中预先确定的几种结果。癫痫发作和格林-巴利综合征是预先选择用于病历确认的。我们使用自我对照风险间隔(SCRI)或历史对照设计来估计发病率比(IRR)。对于没有预先选择进行病历审查的结果,我们使用对结果日期周围的索赔历史进行审查来进一步调查,以确定潜在事件是否可以根据医疗保健模式排除或归因于其他原因。
在 2009-2010 年季节中,未观察到 H1N1 疫苗接种后出现结果的风险显著增加。接种 TIV 后,周围神经系统疾病和神经病的 IRR 略有升高(1.07,95%CI:1.01-1.13)。接种 TIV 后过敏反应的 IRR 为 28.55(95%CI:3.57-228.44)。进一步调查索赔历史后,大多数潜在的过敏反应病例在事件发生时都有其他索赔,表明存在其他解释因素或诊断。在 2010-2011 年季节中,接种 TIV 后观察到过敏反应的非显著升高的 IRR,但没有其他显著的结果发现。
在进行索赔历史审查后,我们最终发现,在 2009-2010 年季节中接种了 998881 剂 TIV 和 538257 剂 H1N1 疫苗,以及在 2010-2011 年季节中接种了 1158932 剂 TIV 后,没有增加结果的风险。